Liberation Bioindustries Pauses Biomanufacturing Plant Again as It Seeks New Funding

Liberation Bioindustries has once again paused construction of its precision fermentation facility in Richmond, Indiana, as it seeks additional financing to complete the project. According to AgFunderNews, the site is approximately 75% finished and is expected to become one of the largest dedicated contract manufacturing facilities for precision fermentation in the United States once operational.

The company said the project remains on budget and in good condition, but completing the final stage requires raising a substantial amount of additional capital. The facility, designed to provide commercial-scale manufacturing services for biotechnology companies, represents a major investment in the growing biomanufacturing sector.

According to AgFunderNews, CEO Etan Bendheim explained that the project has already attracted significant commercial interest. He said the company has expressions of interest representing more than 200% of the plant's available production capacity, demonstrating strong market demand despite the current funding challenge.

The remaining work no longer involves major industrial equipment. Bendheim noted that the fermenters and downstream processing systems have already been installed. The final phase primarily includes electrical systems, plumbing, automation controls and finishing work needed before operations can begin.

To date, Liberation Bioindustries has raised between $70 million and $80 million in equity financing, in addition to securing a large equipment financing package. However, the company finds itself in a difficult position common to first-of-a-kind infrastructure projects.

According to Bendheim, traditional venture capital investors often view projects of this scale as too capital intensive, while conventional project finance lenders typically require operating revenues before committing funds. That creates a financing gap for companies developing new industrial biotechnology infrastructure.

Another major challenge is balancing the expectations of customers and investors. Potential clients want certainty about when the facility will begin operations before signing binding production agreements. Meanwhile, investors seek stronger commercial commitments before providing additional funding.

Bendheim described the situation as a classic "chicken-and-egg" problem. To overcome it, the company is negotiating customized commercial agreements that provide more certainty than non-binding letters of intent while remaining more flexible than traditional take-or-pay contracts.

The facility has been designed around four 150,000-liter fermenters, providing a total fermentation capacity of 600,000 liters. The plant will operate with two independent production trains capable of manufacturing proteins, sweeteners, natural colors and other ingredients using precision fermentation technology.

According to AgFunderNews, the company believes the project remains strategically important despite increasing fermentation capacity coming online in China, India and Europe. Bendheim argued that the United States still needs dedicated commercial-scale precision fermentation infrastructure to support domestic biotechnology companies.

The executive declined to identify most prospective customers but confirmed that Liberation Bioindustries is working with businesses ranging from early-stage startups planning production needs for 2030 to multinational companies seeking near-term manufacturing capacity. Dutch dairy protein company Vivici is one of the few publicly identified potential customers.

Leadership changes have also accompanied the funding process. Mark Warner, who led the development of the Richmond project, is transitioning from his full-time role as Chief Technology Officer to a fractional CTO position. However, he emphasized that the decision should not be interpreted as a loss of confidence in either the company or the project.

Warner stated that the long-term demand for commercial biomanufacturing infrastructure remains strong and praised the project team for keeping construction on budget despite financing challenges. He said the facility continues to be well positioned for success once funding is secured.

The Richmond project illustrates one of the biggest challenges facing the biotechnology industry today: financing large-scale manufacturing infrastructure before predictable commercial revenues are established. If Liberation Bioindustries secures the required investment, the facility could become one of the most significant precision fermentation manufacturing hubs in the United States.